CompletedPhase 1ketamine

Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects

NCT ID

NCT00700076

Target Enrollment

15 participants

Start Date

2008-01-22

Est. Completion

2009-03-09

About This Study

Org 25935 is a new putative antipsychotic agent developed by N.V. Organon.The primary objective of this study is to investigate the effect of Org 25935 on ketamine-induced impairments in immediate recall.

Conditions Studied

Healthy

Interventions

•Ketamine and Org 25935
•Placebo and Ketamine

Eligibility

Sex:MALE

Age:18 Years - 55 Years

Healthy Volunteers:Yes

View full eligibility criteria

Inclusion Criteria:

* Male, 18 - 55 years

Exclusion Criteria:

* History of sensitivity/idiosyncrasy to the drugs used in the study or chemically related compounds or excipients which may be employed in the study or to any other unknown drug used in the past.

Study Locations (1)

Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine

West Haven, Connecticut, United States